Chronic Posterior Laryngitis with suspected Laryngopharyngeal Reflux
Study identifier:SH-NEE-0002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Multicenter, double -blind, Placebo-controlled Study to evaluate the effects of Esomeprazole 40mg bid on the signs and symptoms of Chronic Posterior Laryngitis with suspected Laryngopharyngeal Reflux
Medical condition
Chronic Posterior Laryngitis (CPL)
Phase
Phase 4
Healthy volunteers
No
Study drug
Esomeprazole, Placebo
Sex
All
Actual Enrollment
120
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Feb 2002
Primary Completion Date: 01 Mar 2003
Study Completion Date: 01 Mar 2003
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2011 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: Esomeprazole 40mg orally twice daily Other Name: Nexium |
| Placebo Comparator: 2 | - |
Contacts
Investigators
Principal Investigator
Paula Fernstrom
Nexium Global Product Director, AstraZeneca
